PureTech Health plc (LON:PRTC - Get Free Report) shares passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of GBX 140.42 ($1.82) and traded as low as GBX 128.20 ($1.66). PureTech Health shares last traded at GBX 131 ($1.70), with a volume of 186,057 shares changing hands.
Analyst Upgrades and Downgrades
Separately, Jefferies Financial Group reaffirmed a "buy" rating and set a GBX 455 ($5.89) price target on shares of PureTech Health in a report on Monday, December 16th.
Check Out Our Latest Research Report on PRTC
PureTech Health Stock Performance
The stock has a market cap of £442.16 million, a PE ratio of -6.04 and a beta of 1.02. The stock has a fifty day moving average of GBX 139.75 and a 200-day moving average of GBX 149.81. The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 45.82.
About PureTech Health
(
Get Free Report)
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Featured Articles
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
